Moreover, these therapies can trigger a cytokine storm in the tumor stroma, such as the release of IL-6 and TNF-α, as well as activate macrophages to generate pro-inflammatory mediators to stimulate tumor growth and contribute to recurrence [31, 47, 48]. This evidence concerns the gene IL6 and neoplasm.